Celcuity/$CELC
1D1W1MYTD1Y5YMAX
Capital at risk
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- Ticker
- $CELC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 155
- Headquarters
- Minneapolis, United States
- Website
- www.celcuity.com
Celcuity Metrics
BasicAdvanced
$4B
-
-$4.32
0.20
-
Price and volume
Market cap
$4B
Beta
0.2
52-week high
$151.02
52-week low
$44.42
Average daily volume
814K
Financial strength
Current ratio
8.931
Quick ratio
8.68
Long term debt to equity
-59.004
Total debt to equity
-59.024
Interest coverage (TTM)
-9.37%
Profitability
EBITDA (TTM)
-208.479
Management effectiveness
Return on assets (TTM)
-25.78%
Return on equity (TTM)
-1,433.70%
Valuation
Price to book
-316.56
Price to tangible book (TTM)
-64.44
Price to free cash flow (TTM)
-22.537
Free cash flow yield (TTM)
-4.44%
Free cash flow per share (TTM)
-3.67
Growth
Earnings per share change (TTM)
25.32%
3-year earnings per share growth (CAGR)
18.29%
What the Analysts think about Celcuity
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Analyst projections of the future price of Celcuity stock.
Bulls say / Bears say
Positive topline results from the Phase 3 VIKTORIA-1 PIK3CA mutant cohort showed clinically meaningful PFS improvement in HR+/HER2- PIK3CA MT advanced breast cancer post-CDK4/6 therapy, highlighting gedatolisib’s potential as a novel second-line regimen. (Celcuity)
The PIK3CA MT cohort of VIKTORIA-1 doubled the likelihood of PFS compared to alpelisib plus fulvestrant, supported by a planned Q3 2026 sNDA submission and a preferred Category 1 NCCN guideline recommendation, positioning gedatolisib to capture market share. (Celcuity)
The FDA granted Priority Review for Celcuity’s NDA of gedatolisib in HR+/HER2-/PIK3CA WT advanced breast cancer, assigning a PDUFA date of July 17, 2026, accelerating the regulatory timeline for its wild-type indication. (Celcuity)
Celcuity is a clinical-stage biotechnology company with a limited operating history, having incurred significant losses and lacking any approved or commercially marketed products, making future profitability uncertain. (SEC)
Substantial R&D expenditures and reliance on external financing obligate Celcuity to pursue additional capital raises, which could dilute existing shareholders and exert downward pressure on the stock. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 22 Aug 2026.
Celcuity Financial Performance
Revenues and expenses
Celcuity Earnings Performance
Company profitability
Upcoming events
No upcoming events
Celcuity News
AllArticlesVideos
Funds containing Celcuity
AllEURGBPUSD
Fund name | Fund size | $CELC weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.